Optimum treatment strategies for polyallergic patients – analysis of a large observational trial

Shah‐Hosseini, Kija; Mioc, Katharina; Hadler, Meike; Karagiannis, E.; Mösges, Ralph

doi:10.1185/03007995.2015.1094653

Cited by 12 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None were life-threatening or required the use of epinephrine. The majority of SADRs (30, occurring in six patients) were reported during the first study year, and these have been described previously [21]. Three SADRs occurred in the second study year, all on day 6 in the same patient (a 27-year-old man): pharyngeal edema, throat irritation and sneezing.…”

Section: Resultsmentioning

confidence: 58%

“…The majority (93.1%) of these ADRs occurred during the first study year [21]. The most frequent ADRs were local reactions at the application site, particularly throat irritation, mouth edema and oral paresthesia (Table 3).…”

Section: Resultsmentioning

confidence: 99%

“…patients with clinically relevant symptoms caused by more than one allergen). One-year results from the study showed a significant 49.9% reduction in rhinoconjunctivitis score for the overall population, with similar responses among polyallergic and monoallergic patients [21]. Here, we present the 2-year follow-up data.…”

Section: Introductionmentioning

confidence: 80%

See 2 more Smart Citations

Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study

Shah‐Hosseini

Krudewig

Hadler³

et al. 2017

Adv Ther

Self Cite

View full text Add to dashboard Cite

IntroductionAllergen immunotherapy is the only treatment option for allergic rhinitis with disease-altering potential. It was the objective of this study to assess the effectiveness and tolerability of a 5-grass pollen tablet in a large population of non-selected grass pollen allergic patients, i.e. patients with different clinical profiles in daily clinical practice.MethodsIn a 2-year, prospective, open-label, multicenter, non-controlled, observational study patients were included from 327 centers across Germany. Rhinoconjunctivitis symptoms, symptomatic medication intake and adverse events were recorded.ResultsA total of 1482 patients aged 4–75 years were included. During the 2-year period of 5-grass pollen tablet therapy, mean rhinoconjunctivitis score decreased significantly in the overall study population by 65.5% (P < 0.001). The percentage of patients taking symptomatic medication decreased from 83.8% to 42.7%. Mean 2-year improvements in rhinoconjunctivitis scores and decreases in the percentage of patients taking symptomatic medication were broadly similar in adults, adolescents and children, in patients with polyallergy versus monoallergy, and in patients with/without asthma. Among polyallergic patients, concomitant application of another specific immunotherapy did not impair treatment outcomes. Adverse drug reactions, predominantly affecting the local application area, occurred in 15.4% of the overall patient population (n = 229). No cases of anaphylaxis or epinephrine use were documented.ConclusionThis study indicates that sublingual immunotherapy with the 5-grass pollen tablet is well tolerated and provides sustained effectiveness over 2 years in patients with different clinical profiles, producing a significant decrease in allergic symptoms and a reduction in the use of symptomatic medication.FundingStallergenes GmbH.

show abstract

Section: Resultsmentioning

confidence: 58%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study

Shah‐Hosseini

Krudewig

Hadler³

et al. 2017

Adv Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…The decision for monoallergen vs polyallergen immunotherapy differs by provider and practice region . Several prospective, randomized trials have demonstrated efficacy of both monoallergen and polyallergen immunotherapy for the treatment of polyallergy patients. With the increase in availability of U.S. Food and Drug Administration (FDA)‐approved sublingual immunotherapies, the decision for allergen selection in the setting of polysensitization is controversial.…”

Section: Discussionmentioning

confidence: 99%

Correlation between the number of allergen sensitizations and immunoglobulin E: monosensitization vs polysensitization

Kuperstock

Brook

Ryan

et al. 2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…The results showed that SLIT approximately halved the symptom-medication scores compared to the score registered in drug-treated patients. Since then, several real-life studies were performed, including 11 studies on SCIT (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17), 15 on SLIT (6,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) and 5 on both (30-…”

Section: Real-life Studies On Aitmentioning

confidence: 99%

Allergic reactions after vaccination: translating guidelines into clinical practice

Incorvaia

Barberi

Pastorello

et al. 2019

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

Real-life studies offer the opportunity of obtaining outcomes suitable in clinical practice, as controlled trials do not mirror the real patients' population observed in clinical practice. This concept is particularly appropriate for allergen immunotherapy (AIT). Therefore, the current review will present and discuss the most recent and relevant studies published on this topic. Globally, 15 real-life studies on AIT efficacy are available until now, the total of patients amounts to 9090, with an average number of 699 patients per study. This high number significantly decreases the possibility that the observations from real-life study are casual, and confers to such studies a key role in the next years to assess issues other than efficacy and safety, especially those scantly investigated thus far.sessed by meta-analyses, but the validity and applicability of the observations resulting from RCTs data, especially in the context of real-life settings, is debatable (5). To confirm the applicability to common practice of AIT products demonstrated as effective in RCTs, real-life (also defined real-world) studies are needed. This model was increasingly used in recent years and, especially when based on large populations of patients, provides very useful data to optimize the prescription and the performance of AIT in clinical practice. Here, we will discuss the significance of the outcomes that were achieved in such studies.

show abstract

Optimum treatment strategies for polyallergic patients – analysis of a large observational trial

Abstract: After 1 year of treatment, polyallergic patients responded similarly to the five-grass pollen tablet as monoallergic patients. For polyallergic patients in whom additional treatment was needed, a second SLIT may be more beneficial than a SCIT or symptomatic co-medication.

Cited by 12 publications

References 33 publications

Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study

Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study

Correlation between the number of allergen sensitizations and immunoglobulin E: monosensitization vs polysensitization

Allergic reactions after vaccination: translating guidelines into clinical practice

Contact Info

Product

Resources

About